The data summarized in Evidence Tables I-1 through I-7 are organized based on the specific comparisons made among the monotherapies, as listed below. The code number (left column) identifies each comparison. In the tables, trials are identified by first author's name and year of the principal report. The list below also provides the number of trials and the number of literature citations for each comparison (right column).

Appendix I.Coding Key

Alternatively, the body of literature can be organized by the agents of interest: trials of LHRH agonists and trials of antiandrogens.

Finally, for each principal reference cited in the monotherapy evidence tables, data also may have been derived from additional studies/citations, as can be seen in the following table:

Appendix I. Citation Key for Evidence Tables on Monotherapy

Appendix I. Abbreviation Key for Evidence Tables

Evidence Table I.1. Monotherapies: Interventions and Demographics

Evidence Table I.2. Monotherapies: Overall Survival

Evidence Table I.3. Monotherapies: Progression-free Survival

Evidence Table I.4. Monotherapies: Time to Treatment Failure

Evidence Table I.5. Cardiovascular Adverse Events, Monotherapies

Evidence Table I.6. Endocrine Adverse Events, Monotherapies

Evidence Table I.7. Gastrointestinal Adverse Events, Monotherapies

Evidence Table I.8. Adverse Events Leading to Withdrawal from Therapy, Pooled Results, Monotherapies

Table I.9. Adverse Events Leading to Withdrawal from Therapy, Monotherapies, Randomized Trials

Evidence Table I.10. Adverse Events Leading to Withdrawal from Therapy, Phase II Studies

Evidence Table I.11. Adverse Events by Degree of Severity, Monotherapies

Table I.12. Adverse Events Reported in Package Inserts

Evidence Table I.13. Analysis Data Set for 2-Year Hazard Rates for Prostate Cancer Patientsa

Key to Study Numbers for Evidence Table I.13